Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves ANDA for Lannett Diethylpropion HCl tablets
Diethylpropion HCl, like many anti-obesity drugs, is primarily sold to bariatric clinics, the company said. Lannett president and CEO Arthur P Bedrosian said the approval would add to
Diethylpropion HCl, like many anti-obesity drugs, is primarily sold to bariatric clinics, the company said. Lannett president and CEO Arthur P Bedrosian said the approval would add to
Genzyme will incorporate the Rare Disease business and the Multiple Sclerosis franchise, under the leadership of the new CEO, the company said. David joined Genzyme in 1994 as
AIN457 is a fully human, targeted monoclonal antibody that specifically binds to and neutralizes interleukin-17A (IL-17A), an inflammatory cytokine implicated in many immune-mediated diseases, including psoriasis. The three
TermManager, a code set management and collaborative mapping application, supports healthcare data interoperability initiatives by enabling widespread access to national healthcare vocabulary standards including SNOMED CT, LOINC, ICD,
Both the companies offer services in regulatory affairs, Phase I-IV clinical trial management, and clinical trial site management in China. As part of the acquisition, MedKey/Jiecheng will increase
LDX is a chemically formulated long-acting prescription-only medicine, prodrug of dexamfetamine. The active-controlled, double-blind, dose-optimisation, parallel-group, multicentre, randomised study, which enrolled 336 children and adolescents aged 6 to17
According to Naturex, the acquisition would provide a boost to its industrial base and its ability to meet customer needs. Naturex’s industrial and technological expertise, besides its global
Thermal ceramic compound made from all-natural, clay-based materials can be heated or chilled for on the spot pain therapy or heated for soothing moist heat therapy. Thermionics moist
Under the terms of the Sponsored Research Agreement, Fast Forward will provide funds up to $640,000 to support preclinical testing of MultiStem in murine models of MS enabling
Artemis (AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects), an international, randomized, controlled, open-label, non-inferiority, Phase 3 trial compared the efficacy and safety of Prezista/r versus lopinavir/r in